Interim CHF data....What will it mean, page-29

Back in July last year " Mesoblast Chief Executive Silviu Itescu said: “We believe we can obtain meaningful data by performing a blinded Interim Analysis to assess the heart failure trial’s primary endpoint in Q1 2017. The results will inform our subsequent strategic decisions regarding the program."
But in the last update, sorry I have not time right now to dig out the transcript, I was left with a clear impression that SI downplayed the importance of the readout analysis due any day now. No mention of it having "subsequent strategic decisions impact" I recall clearly at the time on the conference call, make a note to myself of this omission. So taken on face value of what was said back in July, this will be a critical announcement, as if they go forward with a full P3 trial they will need additional funds without a partner.
I also share the view that the other program's without CHF still have potential to make MSB successful but there is no doubt that a decision to pull the plug on CHF or put it on hold will shake confidence in the company and future partnerships maybe hard to come by.
I am waiting in anticipation...........